Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in  vitro.

Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro. Oncol Rep. 2018 Aug 17;: Authors: Li J, Wang J, Yu J, Zhao Y, Dong Y, Fan Y, Li N, Zhang Y, Wang Y Abstract In the present study, we profiled β‑elemene‑regulated gene expression and investigated the effects of the silencing of the DNA polymerase epsilon 2, accessory subunit (POLE2) in lung cancer cells. Differently expressed genes were profiled in A549 cells incubated in the presence or absence of β‑elemene by Affymetrix Human Gene Expression Array. POLE2 shRNA was then constructed to knock down POLE2 expression. Cells were counted and phenotypes were assessed via CCK‑8, colony formation and caspase-3/-7 activity assays. PathScan antibody array analysis was used to identify shPOLE2‑regulated genes. The cDNA microarray identified a total of 721 differentially expressed genes in the A549 cells. Furthermore, knockdown of POLE2 expression inhibited A549 and NCI‑H1299 cell proliferation and apoptosis. The PathScan data indicated that expression levels of p‑Akt (phosphorylated‑protein kinase B, p‑AKT/p‑PKB), p‑Smad2 (phosphorylated mothers against decapentaplegic homolog 2), p‑p38 MAPK (phosphorylated mitogen‑activated protein kinases p38), p‑SAPK/JNK (phosphorylated c‑Jun N‑terminal protein kinase/stress activated protein kinase), cleaved caspase‑7, IκBα (nuclear factor of κ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

-Vila Rafael Rosell BRAF V600 mutations have been found in 1–2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50–80% of BRAF mutations in lung cancer are non-V600, and can be class II, with intermediate to high kinase activity and RAS independence, or class III, with impaired kinase activity, upstream signaling dependence, and consequently, sensitivity to receptor tyrosine kinase (RTK) inhibitors. Plasma cell-free DNA (cfDNA) of 185 newly diagnosed...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion Gefitinib, erlotinib, and afatinib have similar effectiveness in advanced stage N SCLC with EGFR mutation positive. Afatinib tends to be associated with longer PFS but further investigation is required. DOI: 10.3779/j.issn.1009-3419.2019.09.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Conclusion Patients who has lower mutation abundance with EGFR sensitive mutations after TKI treatment may have a longer survival period (P
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Lung cancer is responsible for an estimated 1.7 million deaths worldwide per year, and additional therapeutic options represents an area of unmet need [1,2]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases with adenocarcinoma representing 36% to 60% of cases [3 –5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
vac D Abstract Metabolomics generate a profile of small molecules from plant extracts, which could be directly responsible for bioactivity effects. Using dry-column flash chromatography enabled a rapid and inexpensive method for the very efficient separation of plant extract with a high resolution. This separation method coupled to NMR and FTIR-based metabolomics is applied to identify bioactive natural products. OPLS multivariate analysis method, was used for correlation the chemical composition of the plant extracts, Amphoricarpos autariatus, with the results of cytotoxic activity against Human cervical adenocar...
Source: Talanta - Category: Chemistry Authors: Tags: Talanta Source Type: research
Authors: Zeng, Lin H, Cui J, Liang W Abstract Thymocyte selection-associated high mobility group box (TOX) genes represent a novel family of genes. Deregulated expression of TOXs has been reported in a variety of cancer types, including lung cancer. It has also been reported that TOXs are crucial regulators of the immune system. The present study systematically evaluated the prognostic values of TOX family members using a set of publicly accessible databases, including Oncomine, Kaplan-Meier plotter and cBioPortal. It was revealed that TOX expression profiles differed between lung cancer and normal tissues, and hig...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Tian X, Gao S, Liu Y, Xuan Y, Wu R, Zhang Z Abstract Adenocarcinoma is one of the most common pathological types of human lung cancer and has the highest incidence and mortality rates worldwide. Resistance to paclitaxel (PTX), the standard chemotherapy agent for treatment of lung adenocarcinoma, is a major clinical obstacle. Sensitive markers are urgently required for the diagnosis and characterization of lung cancer, as well as to manage drug resistance. Previous studies have described the activity of long non-coding RNAs (lncRNAs) in human lung cancer and chemotherapy resistance. In previous studies, lnc...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Zhou D, Sun Y, Jia Y, Liu D, Wang J, Chen X, Zhang Y, Ma X Abstract Smoking is one of the most important factors associated with the development of lung cancer. However, the signaling pathways and driver genes in smoking-associated lung adenocarcinoma remain unknown. The present study analyzed 433 samples of smoking-associated lung adenocarcinoma and 75 samples of non-smoking lung adenocarcinoma from the Cancer Genome Atlas database. Gene Ontology (GO) analysis was performed using the Database for Annotation, Visualization and Integrated Discovery and the ggplot2 R/Bioconductor package. Kyoto Encyclopedia ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Sun S, Wu C, Yang C, Chen J, Wang X, Nan Y, Huang Z, Ma L Abstract Mitochondrial transcription termination factors (MTERFs) regulate mitochondrial gene transcription and metabolism in numerous types of cells. Previous studies have indicated that MTERFs serve pivotal roles in the pathogenesis of various cancer types. However, the expression and prognostic roles of MTERFs in patients with non-small cell lung cancer (NSCLC) remain elusive. The present study investigated the gene alteration frequency and expression level using Gene Expression Omnibus datasets and reverse transcription-quantitative polymerase c...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Publication date: Available online 14 September 2019Source: The Annals of Thoracic SurgeryAuthor(s): Ruochuan Zang, Ju-Fang Shi, Toni E. Lerut, Le Wang, Chia-Chuan Liu, Alessandro Brunelli, René Horsleben Petersen, Calvin Sze Hang Ng, Eric Lim, Shugeng Gao, AME Thoracic Surgery Collaborate GroupAbstractBackgroundLung cancer has changed significantly during the past two decades in its epidemiology and treatment. We conducted a retrospective analysis using data from seven major areas of China over ten years to evaluate clinicopathologic and surgical treatment trends of lung cancer in China during the past decadeMethod...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Lung Cancer | Study